Evidence map›Paper›PMID 21750217›Full record

ArticleMolecular cancer therapeutics2011

Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.

Venita Gresham Watson, Nicholas E Hardison, Tyndall Harris, Alison Motsinger-Reif, Howard L McLeod

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Molecular cancer therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Beyond ICJournal of pharmacogenomics & pharmacoproteomics · 2014
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Venita Gresham WatsonUNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nicholas E Hardison
Tyndall Harris
Alison Motsinger-Reif
Howard L McLeod
North Carolina State University · US

Funding

UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6M
POPULATION GENETICS AND DRUG METABOLISMU01GM063340 · NIGMS · WASHINGTON UNIVERSITY · PI MCLEOD, HOWARD L · 2001 to 2009
$17.4M
UNC Clinical and Translational Science AwardUL1TR000083 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2012 to 2013
$11.6M
GRADUATE TRAINING IN BIOINFORMATICST32ES007329 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Fred A. Wright · 2000 to 2026
$6.8M
Genetic Etiology of Cancer Drug ResponseR01CA161608 · NCI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI WILTSHIRE, TIM, WRIGHT, FRED A. · 2012 to 2021
$4.0M
Paclitaxel Carrier from Protein LibraryF31CA119938 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WATSON, VENITA GRESHAM · 2005 to 2010
$128k
NCATS NIH HHS UL1 TR000083NCI NIH HHS F31 CA119938NCI NIH HHS F31 CA1199385NCI NIH HHS R01 CA161608NCRR NIH HHS UL1 RR025747NIEHS NIH HHS 2 T32 ES007329NIEHS NIH HHS T32 ES007329NIGMS NIH HHS U01 GM063340NIGMS NIH HHS U01 GM63340
6 · The paper itself

Abstract

We have attempted to use a familial genetics strategy to study mechanisms of topoisomerase 1 (Top1) inhibition. Investigations have steadily been chipping away at the pathways involved in cellular response following Top1 inhibition for more than 20 years. Our system-wide approach, which phenotypes a collection of genotyped human cell lines for sensitivity to compounds and interrogates all genes and molecular pathways simultaneously. Previously, we characterized the in vitro sensitivity of 15 families of Centre d'Etude Polymorphisme Humain (CEPH) cell lines (n = 142) to 9 camptothecin analogues. Linkage analysis revealed a pattern of 7 quantitative trait loci (QTL) shared by all of the camptothecins. To identify which, if any, QTLs are related to the general mechanism of Top1 inhibition or should be considered camptothecin specific, we characterized the in vitro sensitivity of the same panel of CEPH cell lines to the indenisoquinolones, a structurally distinct class of Top1 inhibitors. Four QTLs on chromosomes 1, 5, 11, and 16 were shared by both the camptothecins and the indenoisoquinolines and are considered associated with the general mechanism of Top1 inhibition. The remaining 3 QTLs (chromosomes 6 and 20) are considered specific to camptothecin-induced cytotoxicity. Finally, 8 QTLs were identified, which were unique to the indenoisoquinolines.

Indexed as

Antineoplastic Agents, PhytogenicCamptothecinCell LineDrug Evaluation, PreclinicalGene Expression ProfilingGenomicsHumansIsoquinolinesOligonucleotide Array Sequence AnalysisQuantitative Trait LociTopoisomerase I InhibitorsAntineoplastic Agents, PhytogenicCamptothecinIsoquinolinesTopoisomerase I Inhibitors

Identifiers

PMID21750217
PMCPMC3191307
OpenAlexW2144103984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.